1 min read
Add as a preferred source on Google

J&J Says Phase 4 Data Showed Tremfya Reduced Pain and Stiffness

The findings involved patients with psoriatic arthritis and axial involvement, with reductions reported at week 24.

A joint model beside an unmarked clinical assessment form / TokenPost.ai
A joint model beside an unmarked clinical assessment form / TokenPost.ai

Johnson & Johnson said Phase 4 data showed Tremfya led to reductions in pain, stiffness, swelling and fatigue among patients with psoriatic arthritis and axial involvement, with findings reported at week 24.

Tremfya, also known as guselkumab, is an interleukin-23 antagonist.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…